Clinical trials: Psoriasis Patients
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Arthritis, Rheumatoid, Arthritis, Psoriatic
A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing
- Trial name
- GO-NICE (NCT01313858)
- Testing
- Simponi®, Methotrexate
- Volunteers
- 1,613 people
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis, Psoriasis
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body.
- Trial name
- NCT06357221
- Testing
- Cetaphil
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Psoriasis
Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)
The survey will be conducted with regard to the following aspects of treatment with Humira (adalimumab) in patients with psoriasis vulgaris and psoriatic arthritis receiving this drug: unknown adverse drug reactions, especially…
- Trial name
- NCT01155570
- Where
- 634 sites in Japan
- Volunteers
- 752 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months…
- Trial name
- NCT00527072
- Testing
- infliximab
- Volunteers
- 217 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
- Trial name
- UNCOVER-2 (NCT01597245)
- Testing
- 80 mg ixekizumab Dosing Regimen, 50 mg etanercept
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 1,224 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Nail Psoriasis, Plaque Psoriasis
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
The purpose of this study is to evaluate if Etanercept administered at a higher initial dose provides greater improvement in nail and skin psoriasis symptoms than a regimen with a lower initial dose.
- Trial name
- NCT00581100
- Testing
- etanercept
- Volunteers
- 136 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Plaque Psoriasis
Plaque Psoriasis Efficacy and Safety With Secukinumab
To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c.
- Trial name
- OPTIMISE (NCT02409667)
- Testing
- Secukinumab
- Where
- 200 sites in Austria, Belgium and 22 more
- Volunteers
- 16,487 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Stable Plaque Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
- Trial name
- EGALITY (NCT01891864)
- Testing
- GP2015 Etanercept, Enbrel
- Where
- 74 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 531 people
- Sponsor
- Sandoz
Psoriasis
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
- Trial name
- NCT00617994
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Psoriasis
Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Primary objective of this study is to compare patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI), two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form…
- Trial name
- NCT00482170
- Testing
- Enbrel (etanercept), Etanercept
- Where
- 78 sites in Belgium, Denmark and 10 more
- Volunteers
- 421 people
- Sponsor
- Pfizer
Psoriasis
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- PHOENIX1 (NCT00267969)
- Testing
- ustekinumab
- Where
- 42 sites in United States, Belgium and 1 more
- Volunteers
- 766 people
- Sponsor
- Centocor Research & Development, Inc.
Palmo-plantar Psoriasis
Apremilast in Palmo-Plantar Psoriasis
This study will compare the safety and efficacy of Apremilast 30mg to placebo in subjects with moderate to severe plaque psoriasis involving palms and/or soles.
- Trial name
- NCT02400749
- Testing
- Apremilast
- Where
- 11 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
This is an open label, investigator-blinded, cross over, prospective, single center study of subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp®…
- Trial name
- PSTaclonex (NCT01707043)
- Testing
- Taclonex
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Psoriasis
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.
- Trial name
- NCT01245140
- Testing
- alitretinoin
- Where
- 8 sites in France, Germany and 2 more
- Volunteers
- 33 people
- Sponsor
- Stiefel, a GSK Company
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Nail Psoriasis
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
- Trial name
- NCT04227288
- Testing
- Enstilar Foam
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham